- Home
- FNGR vs RLMD Comparison
FNGR vs RLMD Comparison
Compare FNGR & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNGR
- RLMD
- Stock Information
- Founded
- FNGR 2016
- RLMD 2004
- Country
- FNGR Singapore
- RLMD United States
- Employees
- FNGR N/A
- RLMD N/A
- Industry
- FNGR Computer Software: Prepackaged Software
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- FNGR Technology
- RLMD Health Care
- Exchange
- FNGR Nasdaq
- RLMD Nasdaq
- Market Cap
- FNGR 108.1M
- RLMD 110.6M
- IPO Year
- FNGR N/A
- RLMD N/A
- Fundamental
- Price
- FNGR $2.08
- RLMD $0.36
- Analyst Decision
- FNGR
- RLMD Hold
- Analyst Count
- FNGR 0
- RLMD 3
- Target Price
- FNGR N/A
- RLMD $5.33
- AVG Volume (30 Days)
- FNGR 205.1K
- RLMD 2.1M
- Earning Date
- FNGR 01-14-2025
- RLMD 11-07-2024
- Dividend Yield
- FNGR N/A
- RLMD N/A
- EPS Growth
- FNGR N/A
- RLMD N/A
- EPS
- FNGR N/A
- RLMD N/A
- Revenue
- FNGR $31,176,174.00
- RLMD N/A
- Revenue This Year
- FNGR $260.03
- RLMD N/A
- Revenue Next Year
- FNGR N/A
- RLMD N/A
- P/E Ratio
- FNGR N/A
- RLMD N/A
- Revenue Growth
- FNGR N/A
- RLMD N/A
- 52 Week Low
- FNGR $1.63
- RLMD $0.35
- 52 Week High
- FNGR $4.36
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- FNGR 52.93
- RLMD 16.59
- Support Level
- FNGR $1.95
- RLMD $0.35
- Resistance Level
- FNGR $2.70
- RLMD $0.41
- Average True Range (ATR)
- FNGR 0.12
- RLMD 0.16
- MACD
- FNGR 0.02
- RLMD -0.11
- Stochastic Oscillator
- FNGR 22.50
- RLMD 0.38
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.